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Background: To investigate the hypothesis that MRI derived diffusion-weighted imaging (DWI) and perfusion (MRP)
parameters are sensitive image biomarkers for monitoring early antiangiogenic effects and predicting progression
free survival (PFS) in advanced hepatocellular carcinoma (HCC).
Methods: In this phase II clinical trial, 23 of 34 patients were included in the imaging and circulating biomarker
study. DWI and MRP were performed at the baseline and at 2-weeks after initiation of sunitinib. The imaging
protocol included an axial DWI sequence using b values of 50, 400 and 800 sec/mm2, and MRP using a series of
coronal 3D-VIBE following 20 ml of Gd-DTPA at 2 ml/sec. These parameters were compared with clinical outcome
and PFS at 6-months. Correlation between changes in MRI parameters and plasma biomarkers was also evaluated.
Results: After 2-week of sunitinib, substantial Ktrans changes in HCC were observed from median baseline value
2.15 min−1 to 0.94 min−1 (P = 0.0001) with increases in median apparent diffusion coefficient (ADC) from 0.88 × 10-3
mm2/s to 0.98 × 10-3 mm2/s (P = 0.0001). Tumor size remained unchanged by RECIST and mRECIST (both P > 0.05).
Patients who showed larger drop in Ktrans and Kep at 2 weeks correlated with favorable clinical outcome, and higher
baseline Ktrans and larger drop in EVF correlated with longer PFS (all P < 0.05). There was a significant association
between a decrease in sVEGFR2 and the drop in Ktrans and Kep (P = 0.044, P = 0.030), and a significant and borderline
association between decrease in TNF-α and the drop in Ktrans and Kep, respectively (P = 0.051, P = 0.035).
Conclusion: In HCC, MRP may be a more sensitive biomarker in predicting early response and PFS following sunitinib
than RECIST and mRECIST.
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Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer and the third most common cause of cancer-
related death worldwide and is responsible for more than
500,000 deaths every year globally [1]. Advanced HCC car-
ries a poor prognosis, and systemic therapy with cytotoxic
agents provides marginal benefit [2,3]. Over the past few
years, significant progress has been made in our under-
standing of the molecular pathogenesis of HCC, which led
to the rationale for the use of novel targeted agents
in clinical trials. Due to highly angiogenic microenviron-
ment in HCC, antiangiogenic agents such as sorafenib,
bevacizumab and cediranib have been tested in clinical tri-
als for the treatment of HCC [4-10]. While sorafenib has
shown increased survival in HCC, other anti-VEGF agents
have shown mixed results [11]. Sunitinib (Sutent; Pfizer,
New York, NY) is an oral multitargeted receptor tyrosine
kinase inhibitor (TKI), which has been approved for the
treatment of renal cell carcinoma, imatinib-resistant
gastrointestinal stromal and pancreatic neuroendocrine
tumors [12]. Although sunitinib demonstrated early evi-
dence of modest antitumor activity in advanced HCC pa-
tients from single arm phase II studies [13], a randomized
phase III trial failed to demonstrate either superiority or
non-inferiority of sunitinib when compared with sorafenib.
This clinical experience indicates that only some patients
benefit from these targeted therapies. The mechanisms of
action in targeted agents, which often cause cytostatic ef-
fect rather than cytotoxic effect, are different from con-
ventional chemotherapy, and therefore, the response
assessment criteria currently in use might be inadequate.
Imaging modalities such as computed tomography (CT)
and magnetic resonance imaging (MRI) are commonly
used in phases II and III clinical trials. They provide reli-
able and reproducible anatomical assessment of changes
in tumor size. However, antiangiogenic therapies for HCC
are known to induce tumor necrosis and may cause no-
change or relative enlargement of the tumor size on im-
aging thereby leading to inappropriate categorization of an
otherwise responsive disease, as stable or progressive
based on established methods such as Response Evalu-
ation Criteria In Solid Tumors (RECIST) [14]. Therefore,
the European Association for the Study of the Liver
(EASL) guidelines recommended that the response criteria
be amended to take into account viable tumor (contrast
enhancement in the arterial phase) [15], and the American
Association for the Study of Liver Disease (AASLD) devel-
oped a set of guidelines that included a formal modifica-
tion of the response assessment based on the RECIST
criteria and aimed to translate into the concept of viable
tumor, which are referred to as modified RECIST
(mRECIST) criteria [16].
With the advancements in MR technology and avail-
ability of commercial software, MR perfusion (MRP) anddiffusion-weighted imaging (DWI) have found their ap-
plications in HCC [17]. DWI uses phase-defocusing and
phase-refocusing gradients, which allow evaluation of
the rate of microscopic water diffusion as a marker of
cellular density and integrity. Using a dynamic MRI,
hemodynamic parameters for permeability measure-
ment, such as transfer constant (Ktrans), redistribution
rate constant (Kep) and extracellular volume fraction
(EVF), can be quantitated [18]. Several studies had
attempted to assess if DWI and MRP derived tumor pa-
rameters could be used for assessment of response to
therapies [12,19-21]. Therefore, we had formulated and
investigated the hypothesis that the DWI or MRP
derived tumor parameters are more sensitive image
biomarkers when compared with tumor burden
measurements as defined by RECIST or mRECIST
in a clinical trial of sunitinib for monitoring early
antiangiogenic effects and predicting progression free
survival (PFS) in advanced HCC. We also postulated that
imaging biomarkers correlate with circulating bio-
markers measured in plasma. Additional objective was
to compare the DWI and MRP parameters of tumor
thrombus and their changes in patients with different
clinical outcome and PFS.
Methods
Patients
The protocol for this phase II clinical trial was in compli-
ance with Health Insurance Portability and Accountability
Act (HIPAA) Regulations and was approved by the The In-
stitutional Review Board (IRB) at Dana Farber Harvard
Cancer Center. All patients were required to provide writ-
ten informed consent before study participation according
to institutional and federal guidelines. Eligibility criteria in-
cluded histologically proven, measurable, locally ad-
vanced, recurrent or metastatic HCC; no more than one
prior systemic regimen; prior chemoembolization therapy
only if performed more than 4 weeks before study entry
and measurable disease present outside of the chemo-
embolization field; age 18 years; Eastern Cooperative
Oncology Group performance status of 0 or 1; Cancer
of the Liver Italian Program (CLIP) score 0–3; and ad-
equate hepatic, renal, and bone marrow function. Ex-
clusion criteria included concurrent malignancies;
significant medical comorbidities; significant cardiovas-
cular disease including uncontrolled hypertension, myo-
cardial infarction, and unstable angina; New York Heart
Association grade 2 or greater congestive heart failure;
prolongation of QTc of more than 450 msec in screening
ECG or history of familial long QT syndrome; history of
bleeding; proteinuria at baseline (more than 2 g/d); preg-
nancy or lactation; central nervous system metastases; or
an inability to provide written informed consent. Thirty-
four patients with advanced HCC were enrolled and 23
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study cohort included 7 men and 16 women (age range,
38 ~ 76 years; median age, 62.6 years).Antiangiogenic treatment
The eligibility, treatment schedule, and dose modifica-
tion schema have been detailed previously [10]. Briefly,
eligible patients received sunitinib at a dose of 37.5 mg
daily by mouth for 28 days followed by 14 days of rest in
6-week cycles. Patients with grade 3 or 4 toxicities under-
went dose reduction to 25 or 12.5 mg daily, respectively.
Treatment was continued until progression, unacceptable
toxicity, or withdrawal of consent. Response and progres-
sion were evaluated using the RECIST after completion
two cycles of sunitinib therapy.Imaging protocol
This clinical trial was designed not only to investigate the
role of DWI and MRP for monitoring early antiangiogenic
treatment effects but also to study the overall survival and
PFS. The DWI, MRP and delayed postcontrast T1-
weighted images were performed at base line and two
weeks after initiation of antiangiogenic treatment. A re-
staging contrast-enhanced MRI (CE-MRI) was performed
at the end of cycle 2 treatment with sunitinib for response
status and then at every 6-weeks until disease progression.
The data acquisition parameters, the same injection proto-
col and the anatomic location for scanning, including the
total duration, were kept constant for each patient and for
each repeat DWI, MRP and CE-MRI study.DWI
DWI of the liver was performed using a phased array
body coil on a 1.5-T MRI system (Avento; Siemens, New
York, NY) using the following protocol. T1-weighted
in-phase and out- of-phase images (repetition time
(TR)/ echo time (TE), 122 ~ 159/2.38 ~ 4.72 msec; one
signal acquired; flip angle, 70 degree; 20 slices; section
thickness, 5 ~ 7 mm; 1-mm interslice gap) and axial
respiratory-triggered fast spin-echo T2-weighted images
(TR/TE, 3500 ~ 4494/65 ~ 85 msec; one signal acquired;
flip angle, 53 degree; echo train length, 15; 20 slices;
section thickness, 5 ~ 8 mm; 1-mm interslice gap) were
acquired first. Thereafter, an axial respiratory-gated
echo-planar diffusion-weighted (DW) sequence with spec-
tral fat saturation was performed by using the follow-
ing parameters: b values of 50, 400 and 800 sec/mm2;
TR/TE, 4959 ~ 7936/44 ~ 74 msec; two signals acquired;
echo train length, 1; flip angle, 60 ~ 90 degree; 20 slices;
section thickness, 5 ~ 8 mm; 1-mm interslice gap; field of
view, 263 × 350; matrix, 144 × 192. The total acquisition
time is 3 ~ 6 min.MRP
MRP of the liver was performed using a phased array body
coil on the same 1.5-T MRI system (Avento; Siemens, New
York, NY) using the following protocol. At first, three
dimensional volume interpolated excitation coronal T1
sequence (VIBE) was obtained in a breath hold before
contrast media injection using the following parameters:
TR = 5 msec, TE = 1.58 msec, 5-mm slice thickness, 1-mm
interslice gap, 20 slices, 123 × 192 matrix, and field of view
of 400 × 400 mm. Thereafter, through the 20-guage periph-
eral intravenous line in the arm, 0.1 mmol/kg body weight
of gadopentetate dimeglumide contrast media (Magnevist;
Berlex, Montville, NJ) was power injected at 2 mL/sec,
followed by a saline chase of 20 mL at a rate of 2 mL/sec.
Then, MRP acquisition was performed. A series of cor-
onal T1-weighted three-dimensional volume interpolated
excitation (VIBE) images were obtained after 5-second
delay after the initiation of contrast media injection, and
the scanning continued for up to 4 minutes and 40 sec-
onds. The acquisition parameters included: TR = 5 msec,
TE = 1.58 msec, 5-mm slice thickness, 0-mm interslice gap,
20 slices, 123 × 192 matrix, 15-degree flip angle, and field
of view of 400 × 400 mm. Two consecutive 7-second acqui-
sitions forming two different time points were repeated 10
times with a delay of 14 seconds between them. The scan-
ning time in every acquisition was 14 seconds with a break
of 14 seconds, and the patients were asked to hold their
breath during acquisition. Finally, delayed postcontrast T1-
weighted images were taken as follows: axial and coronal
two-dimensional T1-weighted fat-saturated gradient echo
(GRE) sequences using TR = 150 msec, TE = 2.1 msec,
160 × 256 matrix, 20 slices, 5-mm thickness, and 0-mm
interslice gap. For the measurement of tumor burden and
diameter of tumor thrombus in portal vein, postcontrast
T1-weighted images were applied.CE-MRI
CE-MRI of the liver was performed using a phased
array body coil on the same 1.5-T MRI system (Avento;
Siemens, New York, NY) using the following protocol.
A total of 0.1 mmol/kg body weight of gadolinium-
diethylenetriaminepentaacetic acid (Gd-DTPA) contrast
media (Magnevist; Berlex, Montville, NJ) was power
injected at 2 mL/sec, followed by a saline chase of 20 mL
at a rate of 2 mL/sec. The arterial, portal and delayed
phase scanning were performed after 35, 65 and 280
seconds from the initiation of contrast medium bolus.
Three dimensional volume interpolated excitation axial
T1 sequence was obtained in a breath hold after con-
trast media injection using the following parameters:
TR = 5 msec, TE = 1.58 msec, 5-mm slice thickness, 0-mm
interslice gap, 20 slices, 123 × 192 matrix, and field of view
of 400 × 400 mm.
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Data were processed at a picture archiving and communi-
cation system (PACS) (Impax 4.0; Agfa, Mortsel, Belgium)
by two experienced radiologists with 13 and 10 years of
experience in liver imaging. To obtain permeability maps,
MRP images were processed at pixel resolution by using a
commercially available full time point (fTP) model (iCAD
Sciences, White Plains, NY) to analyze the time evolution
of contrast enhancement.
Tumor size was measured in the longest cross-sectional
dimension for each lesion based on RECIST 1.1 guidelines.
And viable tumor diameter was measured in the longest
cross-sectional dimension for enhancing component of
each lesion based on mRECIST guidelines. The sum of the
longest dimensions of selected target lesions in each pa-
tient was computed, and the absolute and percent changes
of the sum from the baseline to post treatment evaluation
were computed for each patient. Diagnostic standard and
diameter measurement for tumor thrombus in portal vein
was referred to the criteria described by Shah et al. [22].
The apparent diffusion coefficient (ADC) map was auto-
matically generated on the imager console from the DWI
sequence; the selected b values (50, 400 and 800 sec/mm2)
were used for ADC quantification. For ADC quantitative
analysis, the nonenhanced images showing the maximal
diameter of the HCC and the maximal diameter of the
tumor thrombus in the portal vein were respectively se-
lected as reference [23]. Definitions of MRP parameters
and the model used for generating functional maps were
described as before [24,25]. Briefly, for each MRP acquisi-
tion, the fTP-pharmacokinetic image analysis platform im-
plements the Tofts pharmacokinetic model to quantify
vascular permeability (Ktrans, EVF and Kep).
On DWI and MRP postprocessed images, we manu-
ally drew region of interests (ROI) in all the anatomic
locations from the section in which the tumor was first
visible to the last section in which the tumor was visible
to enable whole tumor evaluation, and corresponding
values were acquired. ROI included at least two-thirds
of the area of the HCC and at least three-fourths of the
area of the thrombus in the portal vein. To minimize
volume averaging, we enlarged the images and placed
the ROI within the thrombus. Care was taken to avoid
including in the ROI any area outside the HCC and the
thrombus. For patients with multiple lesions, we drew
ROI for all and computed a median value for analysis
of parameters. Then, the absolute and percent changes
in ADC value and MRP parameters from the baseline
and after therapy were calculated for each patient.
Circulating biomarkers
For measurement of angiogenic proteins and inflamma-
tory cytokines in plasma, peripheral blood was obtained
at baseline and 14 days after the first dose of sunitinib.All samples were collected in ethylenediaminetetraacetic
acid (EDTA)-containing Vacutainers. Plasma analysis
was carried out for circulating vascular endothelial
growth factor (VEGF), placental-derived growth factor
(PlGF), soluble VEGF receptor (VEGFR) 1, basic fibroblast
growth factor (bFGF), interleukin (IL)-1β, IL-6, IL-8, and
tumor necrosis factor α (TNF-α) using multiplex array
plates from Meso-Scale Discovery (Gaithersburg, MD),
and for soluble VEGFR2, soluble VEGFR3, stromal-
derived factor 1α (SDF1α), VEGF-C, and soluble c-KIT
from R&D Systems (Minneapolis, MN) [12]. Samples
were run in duplicate.Statistical analysis
Data were analyzed using SPSS statistical software, ver-
sion 10.0, SPSS Inc, Chicago, IL and R (R Foundation
for Statistical Computing, Vienna, Austria). We present
medians with ranges of various parameters of the HCC
and tumor thrombus at baseline and following
antiangiogenic treatment. Changes in ADC value and
MRP parameters of HCC and tumor thrombus as well
as tumor burden measures were expressed as percent
changes and tested statistically using paired exact
Wilcoxon signed rank test for comparison at the base-
line and at the 2 weeks after initiation of treatment. For
correlation with clinical outcome, patients were divided
into two groups: those with progressive disease (PD)
and those with either stable disease (SD) or a partial re-
sponse (PR). Similarly, for correlation with PFS, pa-
tients were divided into two groups: those with PFS ≤ 6
months and those with PFS>6 months. The baseline values
and percent changes in various parameters after sunitinib
administration in these groups were compared using the
two-sample exact Wilcoxon rank sum test. Correlation be-
tween changes in MRI parameters and plasma biomarkers
at day 15 after sunitinib treatment in advanced HCC pa-
tients was performed using Kendall’s correlation coeffi-
cients. In this study, a P-value of less than or equal to 0.05
was considered to indicate a statistically significant
difference.Results
The clinical outcome of patients from the phase II trial
has been previously reported [10]. Briefly, of the 23 pa-
tients enrolled in the current study who were evaluable
for efficacy after completion two cycles of sunitinib ther-
apy, one (4.4%) had a confirmed PR and 15 (65.2%) had
SD, the other 7 (30.4%) showed PD. In 14 patients
(60.9%) PFS ≤ 6 months was encountered and the other
9 had PFS>6 months (39.1%). In addition, 9 of 23 pa-
tients (39.1%) were categorized as having tumor throm-
bosis; 5 (55.6%) showed PFS ≤ 6 months and the other 4
had PFS>6 months (44.4%).
Table 1 Tumor and tumor thrombus size, DWI and MRP parameters at baseline and post antiangiogenic treatment
Parameters Baseline (Median, Range) Post-sunitinib (Median, Range) P value
SIZE
RECIST 10.00, 2.30 ~ 17.00 11.10, 1.30 ~ 25.00 0.197
m RECIST 9.94, 2.15 ~ 19.56 10.11, 2.11 ~ 18.55 0.963
Tumor thrombus(mm) 28.67, 21.87 ~ 36.63 29.81, 21.98 ~ 37.73 0.365
DWI
HCC ADC (×10-3 mm2/s) 0.88, 0.58 ~ 1.09 0.98, 0.75 ~ 1.21 <0.0001
Tumor thrombus ADC (×10-3 mm2/s) 0.89, 0.60 ~ 1.14 1.02, 0.78 ~ 1.26 0.035
MRP
HCC Ktrans (min−1) 2.15, 0.90 ~ 4.81 0.94, 0.57 ~ 2.30 <0.0001
Kep (min−1) 2.61, 1.00 ~ 41.75 1.22, 0.66 ~ 2.64 <0.0001
EVF 0.926, 0.34 ~ 1.00 0.81, 0.65 ~ 0.97 0.079
Tumor thrombus Ktrans (min−1) 1.89, 0.93 ~ 2.99 0.99, 0.37 ~ 1.61 0.110
Kep (min−1) 2.37, 1.05 ~ 4.03 1.49, 0.61 ~ 2.37 0.190
EVF 0.83, 0.70 ~ 0.98 0.66, 0.56 ~ 0.77 0.055
Abbreviations: Ktrans Transfer constant; Kep Rate constant; EVF Extracellular volume fraction; ADC Apparent diffusion coefficient.
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and after 2-week of sunitinib therapy in HCC and tumor
thrombus
The tumor parameters at baseline and 2-week post-
sunitinib therapy are shown in Table 1. There wasFigure 1 Functional transfer constant map of HCC during sunitinib the
transfer constant (Ktrans) maps from MR perfusion (C, D) at baseline and aft
After two weeks of treatment with sunitinib, HCC showed a 96% drop of Ktrminimal change in median tumor burden based on
RECIST (from 10.00 cm to 11.10 cm, P = 0.197) and
mRECIST (from 9.94 cm to 10.11 cm, P = 0.96) and
median tumor thrombus diameter (from 28.67 mm to
29.81 mm, P = 0.365). There was an increase inrapy. Coronal enhanced MR T1-weighted images (A, B) and functional
er 2-week of sunitinib therapy in a 47-year-old man with HCC (arrows).
ans, which presented a conspicuity of permeability change.
Figure 2 MR diffusion weighted images during sunitinib therapy. Transverse enhanced MR T1-weighted images (A, B) and MR diffusion
weighted images (DWIs) for estimated apparent diffusion coefficient (ADC) (C, D) at baseline and after 2-week of sunitinib therapy in the same
47-year-old man with HCC (arrows). After two weeks of treatment with sunitinib, there was an increase in ADC value from 0.86 × 10-3 mm2/s to
0.94 × 10-3 mm2/s.
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0.98 × 10-3 mm2/s (P < 0.0001) and in median tumor
thrombus ADC value from 0.89 × 10-3 mm2/s to 1.02 × 10-
3 mm2/s (P = 0.035). The Ktrans change of HCC in MRP
was more substantial with a decrease from median
baseline value of 2.15 min−1 to 2-week post-treatment
value of 0.94 min−1 (P < 0.0001). The HCC also showed
relatively higher median Kep at baseline (4.15 min−1)
and a significant decrease compared with post-
treatment value (1.44 min−1) (P < 0.0001). The tumor
thrombus displayed similar diffusion and perfusion fea-
tures as their primary HCC at baseline and after treat-
ment. The examples of Ktrans and ADC changes in an
indexed HCC lesion after sunitinib administration are
illustrated in Figures 1 and 2.
Correlation of baseline and percent changes in DWI and
MRP parameters with clinical outcome
For correlation with clinical outcome, patients were di-
vided into two groups: responders (RR) and nonre-
sponders (NR) after completion of 2-cycles (12 weeks)
of sunitinib therapy in 23 patients. 16 (69.6%) were
classified as RR (PR + SD) and the remaining 7 as NR(PD, 30.4%). In the RR, median baseline RECIST and
mRECIST derived tumor burden was 9.50 cm and
10.14 cm with a median percent change of 1.15% and
1.94%, whereas in the NR the median tumor burden
was 10.30 cm with a median percent change of 33.98%
(baseline P = 0.255 and percent change P = 0.0002) for
RECIST and 6.12 cm with a median percent change of
0.49% (baseline P = 0.290 and percent change P =
0.360). The median baseline tumor thrombus diameter
in RR and NR was 26.42 mm and 31.48 mm (P = 0.110)
without any significant change at the end of sunitinib
treatment (−10.22% and 7.72%, P = 0.260). Likewise, al-
though the median baseline ADC value was relatively
higher in NR, there was no significant difference in the
median baseline ADC value as well as the median per-
cent change of HCC and tumor thrombus between RR
and NR.
In contrast, Ktrans in RR showed significantly larger
median percent change (−54.98%) than NR (−17.83%)
(P = 0.014). Similarly, Kep in RR showed significantly
larger median percent change (−42.06%) than NR
(−24.21%) (P = 0.048). Moreover, the median percent
Ktrans change of tumor thrombus in RR (−55.00%) was
Table 2 Correlation of DWI and MRP parameters with clinical outcome in HCC and tumor thrombus
Baseline Percent changes (%)










HCC (cm) 9.50, 2.30 ~ 17.00 10.30, 4.30 ~ 10.3 0.255 1.15, –43.48 ~ 8.46 33.98, 20.71 ~ 58.23 0.0002
Tumor thrombus(mm) 26.42, 22.14 ~ 30.70 31.48, 24.65 ~ 38.34 0.110 −10.22, –25.62 ~ 10.26 7.72, –28.52 ~ 42.92 0.260
mRECIST
HCC (cm) 10.14, 2.15 ~ 19.56 6.12, 2.24 ~ 15.86 0.290 1.94, –19.80 ~ 15.86 0.49, –19.84 ~ 6.70 0.360
DWI
HCC ADC (×10-3 mm2/s) 0.86, 0.58 ~ 0.99 0.93, 0.8 ~ 1.09 0.15 22.42, –8.99 ~ 51.72 22.22, –12.84 ~ 25.81 0.300
Tumor thrombus ADC (×10-3 mm2/s) 0.66, 0.60 ~ 0.73 0.96, 0.79 ~ 1.14 0.290 13.34, –13.28 ~ 39.94 20.32, –62.33 ~ 114.23 0.140
MRP
HCC Ktrans (min−1) 2.35, 0.90 ~ 4.81 1.29, 1.00 ~ 2.80 0.402 −54.98, –83.37 ~ –10.00 −17.83, –72.09 ~ –6.00 0.014
Kep (min−1) 4.25, 1.00 ~ 41.75 1.54, 1.00 ~ 3.01 0.18 −54.73,– 96.32 ~ −5.04 −12.19, –70.17 ~ 28.04 0.048
EVF 0.83, 0.34 ~ 1.00 0.95, 0.84 ~ 1.00 0.065 −2.38, –47.50 ~ 61.76 -6.45, –27.37 ~ –2.38 0.331
Tumor thrombus Ktrans (min−1) 1.96, 0.93 ~ 2.99 1.73, 1.05 ~ 2.41 0.350 −55.00, –72.65 ~ −47.35 −20.04, –63.23 ~ 24.14 0.006
Kep (min−1) 2.54, 1.05 ~ 4.03 1.97, 1.18 ~ 2.76 0.230 −45.53, –67.42 ~ −23.64 −30.58, –80.01 ~ 18.98 0.090
EVF 0.81, 0.70 ~ 0.92 0.89, 0.82 ~ 0.98 0.110 −15.70, –31.95 ~ 0.56 −29.65, –38.12 ~ −21.07 0.060
Abbreviations: Ktrans Transfer constant; Kep Rate constant; EVF Extracellular volume fraction; ADC Apparent diffusion coefficient; SD Partial disease; PR Partial
response; PD Progressive disease.
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median baseline as well as the median percent changes
of EVF values in HCC and tumor thrombus didn’t show
any significant difference between RR and NR







HCC (cm) 10.00, 5.20 ~ 14.00 10.00, 2.30 ~ 17.0
Tumor thrombus(mm) 23.87, 22.14 ~ 28.50 30.79, 24.65 ~ 38.
mRECIST
HCC (cm) 10.70, 2.15 ~ 19.56 9.66, 2.24 ~ 15.86
DWI
HCC ADC (×10-3 mm2/s) 0.83, 0.65 ~ 1.01 0.90, 0.69 ~ 1.09
Tumor thrombus ADC (×10-3 mm2/s) 0.74, 0.60 ~ 1.03 0.93, 0.79 ~ 1.14
MRP
HCC Ktrans (min−1) 2.80, 1.00 ~ 4.81 1.70, 0.90 ~ 4.1
Kep (min−1) 3.01, 1.00 ~ 41.75 2.79, 1.27 ~ 4.36
EVF 0.93, 0.57 ~ 1.00 0.88, 0.34 ~ 1.00
Tumor thrombus Ktrans (min−1) 1.65, 0.93 ~ 2.33 1.98, 1.05 ~ 2.99
Kep (min−1) 2.43, 1.32 ~ 4.03 1.95, 1.05 ~ 2.76
EVF 0.78, 0.70 ~ 0.92 0.88, 0.82 ~ 0.98
Abbreviations: Ktrans Transfer constant; Kep Rate constant; EVF Extracellular volumeCorrelation of baseline and percent changes in DWI and
MRP parameters at 2-weeks with PFS
We then examined the correlation of baseline and per-
cent changes in DWI and MRP parameters with PFS.
The median PFS time of study cohort was 4.6 monthsHCC and tumor thrombus
Percent changes (%)
)





0 0.682 3.57, –36.54 ~ 35.00 7.60, –43.48 ~ 58.23 0.875
34 0.114 −15.23, –25.62 ~ 10.26 9.72, –28.52 ~ 42.92 0.019
0.207 −0.88, –11.16 ~ 11.00 1.89, –19.84 ~ 15.86 0.517
0.570 19.48, –12.84 ~ 40.00 22.22, –8.99 ~ 51.72 0.825
0.085 10.38, –13.28 ~ 39.94 21.11, –62.33 ~ 114.23 0.315
0.043 −52.27, –83.37 ~ −7.00 −41.25, –75.61 ~ -6.00 0.467
0.100 −49.58, – 96.32 ~ 28.04 −46.33, –77.05 ~ -1.67 0.914
0.590 −8.77, –47.50 ~ 20.55 –2.38, –30.12 ~ 61.76 0.022
0.374 −58.48, –72.65 ~ −47.35 −23.11, –63.23 ~ 24.14 0.005
0.220 −42.53, –67.42 ~ −23.64 −34.58, –80.01 ~ 18.98 0.135
0.120 −11.30, –31.95 ~ 0.56 −22.43, –38.12 ~ −19.75 0.331
fraction; ADC Apparent diffusion coefficient.
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the updated overall survival time was 9.9 months (95%
CI, 7.5 ~ 14.1 months). The PFS rate at 6 months was
39.1%.
The median baseline ADC value was relatively higher
in patients with PFS ≤ 6 months but not statistically dif-
ferent from the median baseline ADC value as well as
the median percent change of HCC and tumor thrombus
between these two groups.
In contrast, the median baseline Ktrans in patients
with PFS > 6 months (2.80 min−1) was significantly
higher than that in those with PFS ≤ 6 months (1.70 min−1)
(P = 0.043). Moreover, the median percent change of tumor
thrombus in patients with PFS > 6 months (−58.48%)
was also larger than those with PFS ≤ 6 months (−23.11%)
(P = 0.005). The median percent changes of EVF value inTable 4 Correlation between changes in MRI parameters
and plasma biomarkers after sunitinib treatment
(Kendall’s τ correlation coefficients)
Kendall’s τ Ktrans Kep EVF ADC
VEGF 0.00* 0.11 0.03 0.24
P-value 1.00 0.49 0.86 0.13
PlGF 0.00 0.10 −0.06 0.06
P-value 0.74 0.53 0.72 0.72
sVEGFR1 0.22 0.18 −0.16 −0.16
P-value 0.16 0.26 0.30 0.30
sVEGFR2 0.33 0.35 −0.05 −0.19
P-value 0.044 0.030 0.77 0.24
sVEGFR3 0.00 −0.09 0.24 −0.23
P-value 1.00 0.62 0.21 0.22
VEGF-C 0.17 0.17 0.02 −0.01
P-value 0.28 0.29 0.90 0.95
bFGF 0.17 0.15 0.01 −0.06
P-value 0.28 0.45 0.86 0.72
TNF-α 0.32 0.34 0.01 −0.17
P-value 0.051 0.030 0.97 0.30
SDF1α 0.02 0.14 0.12 0.26
P-value 0.90 0.38 0.47 0.10
IL-1β 0.16 0.14 0.16 −0.02
P-value 0.33 0.38 0.31 0.90
IL-6 0.01 −0.04 −0.04 −0.13
P-value 0.95 0.82 0.82 0.44
IL-8 0.10 0.08 0.04 −0.21
P-value 0.56 0.63 0.82 0.19
Sol c-KIT 0.20 0.12 −0.01 0.01
P-value 0.20 0.45 0.95 0.95
*Positive values of Kendall’s τ indicate a direct correlation between changes
after treatment (relative to baseline) in imaging biomarkers and
plasma biomarkers.HCC showed a significant correlation with PFS (P = 0.022)
(Table 3).
Changes in vascular permeability measured by MRI and
circulating biomarkers
The changes in circulating biomarkers at 2 weeks after
sunitinib treatment have been reported elsewhere [10].
When we compared the change in MRI parameters with
the change in plasma angiogenic and inflammatory cyto-
kines we found a significant correlation between decrease
in sVEGFR2 or TNF-α and a drop in Kep (P = 0.030 and
P = 0.035 respectively) and a similar correlation for the
decrease in Ktrans (P = 0.044 and P = 0.051 respectively).
There was no other association between the changes in
MRI parameters and circulating biomarkers at this time-
point (Table 4).
Discussion
The RECIST based change in tumor burden following
treatment with chemotherapy is a widely accepted im-
aging surrogate for assessing treatment outcome in on-
cologic clinical trials. Its ease of use, quantization and
reproducibility has been the major attribute for its suc-
cess. Due to deficiencies in RECIST for evaluating treat-
ment efficacy in HCC, the criteria have been modified
(mRECIST) to include arterial phase enhancement of
the lesion [16]. However, novel targeted antiangiogenic
approaches may induce necrosis and stabilize tumor
growth rather than tumor regression, which makes the
early response evaluation challenging. In this context,
there has been an increase in the utilization of MRP
in HCC, including for monitoring early therapeutic ef-
fects after a few days/weeks of antiangiogenic treat-
ment [12,26,27]. An advantage of the MRP technique
is that it can be incorporated into routine conven-
tional MRI providing physiological information. More-
over, MRP coupled with powerful and user-friendly
software packages can offer excellent contrast resolution,
more coverage, repeated examinations and continuous
sampling of data for more than four minutes, which al-
lows the assessment of washout without exposure to ion-
izing radiation.
In this study, we observed that the MRP derived HCC
parameters (Ktrans and Kep) were more sensitive imaging
biomarkers than ADC value, RECIST, and mRECIST for
monitoring early antiangiogenic treatment effects. Ktrans
(wash-in rate) describes the leakage rate of the contrast
medium. For blood vessels where leakage is rapid, that is,
when extraction fraction during the first pass of the con-
trast agent is high, perfusion will determine contrast agent
distribution and Ktrans approximates to tissue blood flow
per unit volume [25]. Whereas, Kep measures the rate of
contrast agent diffusion back into the vasculature (wash-
out rate) from where it is excreted [25]. Higher baseline
Sahani et al. Journal of Hematology & Oncology 2013, 6:51 Page 9 of 11
http://www.jhoonline.org/content/6/1/51Ktrans value and more substantial drop in Ktrans and Kep
at 2 weeks after therapy correlated with better clinical out-
come or PFS. Our results support the hypothesis that after
antiangiogenic therapy, the changes in tumor perfu-
sion precede the change in tumor size, which make
the MRP parameters more sensitive for monitoring early
antiangiogenic effects compared with tumor burden mea-
surements as defined by RECIST or mRECIST in advanced
HCC. The reduced tumor vessel permeability as estimated
by MRP indicated a direct effect on HCC microvasculature
that might be associated with clinical benefit after sunitinib
therapy. Similar observations have been reported by de
Langen AJ et al. in patients with advanced non-small cell
lung cancer treated with bevacizumab and erlotinib [28].
In advanced HCC, DCE-MRI demonstrated reduction in
Ktrans during antiangiogenic treatment and the change of
Ktrans during treatment was related to better PFS and OS
in clinical trials of sorafenib [26,27]. The change of Ktrans
may reflect the underlying tumor permeability changes in-
duced by antiangiogenic therapy. This suggests that control
of vessel leakiness may be a determinant of HCC response
to sunitinib [28,29].
In addition, we found the higher baseline of Ktrans can
even relate with longer PFS. Similar studies on the predict-
ive value of tumor perfusion parameters have also been
reported. In cervical cancer, the MRP parameters quantify-
ing permeability status can provide very early prediction of
tumor control and disease-free-survival [30]. The MRP pa-
rameters such as Ktrans depend on vascular permeability
and are being considered as imaging biomarker because
they can detect functional changes in tumor vasculature
after treatment with anti-VEGF agents [31]. The increased
concentration gradient across the endothelial membrane,
the larger surface area of the vascular endothelium to
which they are exposed, the higher endothelial permeabil-
ity, the loss of cell membrane integrity and higher cellular
density can all contribute to the relatively higher baseline
permeability values in responders and patients with longer
PFS [25,32,33].
Increase in ADC in response to sunitinib therapy is
consistent with the observations made by other investi-
gators on ADC increase in liver tumors to other non-
surgical treatments and is believed to result from loss of
cell membrane integrity or necrosis [34,35]. However,
the median baseline value and the percent change of
ADC did not correlate with the clinical outcome and
PFS. It is possibly due to higher biologic aggressive-
ness and presence of tumor necrosis. Poor perfusion is
known to impede drug delivery and induce hypoxic and
acidic environment, which diminishes the effectiveness of
antiangiogenic therapy [36,37]. In addition, following
antiangiogenic therapy, improvement of tumor perfusion,
edema and inflammation may be the dominant factor to
influence the ADC values instead of necrosis and loss ofcell membrane integrity that often follows much later in
the course of system chemotherapy [38]. This potentially
explains mild changes in ADC in comparison to more
significant changes in Ktrans and Kep.
Interestingly, we also found that tumor thrombus
showed high baseline values and substantial reduction in
perfusion parameters following sunitinib treatment almost
similar to the response in the primary tumor. The accurate
differentiation of bland from tumor thrombus is crucial for
patient treatment. Although a neoplastic thrombus can be
discriminated from a clot in most cases by CE-MRI alone,
characterization of small thrombi or a peripheral one can
be difficult on conventional MR alone. Our results support
the tissue characterization benefits of MRP parameters as
well as DWI, which could potentially be applied in differ-
entiating tumor thrombus from bland thrombus [23].
Moreover, tumor thrombus could be the only visible evi-
dence of measurable disease and might be used for re-
sponse evaluation.
Signaling through VEGFR2 in endothelial cells is crit-
ical in VEGF-induced vascular leakiness [39,40], and a
decrease in circulating sVEGFR2 has been consistently
seen with all agents that block this pathway [10,41,42].
Similarly, TNF-α—a pro-inflammatory cytokine—is known
to increase vascular permeability [43]. The preliminary
finding that the changes in MRI parameters are associ-
ated with the changes in circulating sVEGFR2 and
TNF-α suggests that the rapid drop in vessel leakiness
in HCC after sunitinib treatment may potentially occur
by direct blockade of VEGF/VEGFR2 signaling or indir-
ectly by reduction of TNF-α. In this study, Kep showed
significant correlations with both VEGFR2 and TNF-α,
whereas Ktrans showed a significant correlation with
only VEGFR2. There was a trend for correlation be-
tween Ktrans and TNF-α, but it did not reach statistical
significance, which may be due to the small sample size
of this study. These associations should be tested in lar-
ger prospective studies.
It should be noted that our study has a few limitations.
First, the sample size is relatively small and the predict-
ive value of Ktrans and Kep remains to be validated in
larger prospective studies. In addition, the diagnosis of
tumor invasion in the portal vein was based on well-
established imaging criteria of portal vein expansion and
appreciable enhancement in the thrombus and not on
histopathologic sampling.
Conclusions
Our experience from this phase II study suggests that
following antiangiogenic therapy in advanced HCC, im-
aging changes are detectable within 2 weeks on DWI
and MRP-derived parameters. Moreover, larger percent
drops in Ktrans and EFV – but not the changes in tumor
burden – correlated with longer PFS, which suggests that
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sponse for antiangiogenic therapy in HCC. These results
may be specific to the method of analysis and the software
employed in this study and warrant validation in future
studies. However, these data indicate that MRI-based eval-
uations of tumor diffusion and perfusion and circulating
biomarker evaluation will not only provide a better mech-
anistic understanding of the effects of antiangiogenic ther-
apies, but will also facilitate tumor response assessment.
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